THE RESPONSE TO ANAPLASTIC LYMPHOMA KINASE INHIBITOR IN METASTATIC ANAPLASTIC THYROID CARCINOMA.
Ab Muin NF1, Ho GF2.
1Radiotherapy & Oncology Department, Hospital Canselor Tuanku Muhriz, Faculty of Medicine, Universiti Kebangsaan Malaysia.
2Clinical Oncology Department, University of Malaya Medical Centre, Faculty of Medicine, University of Malaya.
Anaplastic thyroid carcinoma is an undifferentiated tumour and lethal. Conventional treatment has not demonstrated clear therapeutic efficacy in prolonging the survival in metastatic anaplastic thyroid carcinoma. We report a case of a 44-year-old woman who was diagnosed with stage IV anaplastic thyroid carcinoma with positive anaplastic lymphoma kinase-echinoderm microtubule-associated protein-like-4 mutation. She demonstrated a good response to anaplastic lymphoma kinase inhibitors therapy with stable disease status for more than six months. This case report shows clinical efficacy of anaplastic lymphoma kinase inhibitor in a patient with stage IVC anaplastic thyroid carcinoma with positive anaplastic lymphoma kinase mutation.
Keywords: Anaplastic Thyroid Carcinoma, ALK Inhibitor, Ceritinib, Alectinib, Tyrosine Kinase Inhibitor.
Corresponding author: Nur Fa’izah Ab Muin, Oncology & Radiotherapy Department, Pusat Perubatan Universiti Kebangsaan Malaysia, Jalan Yaacob Latif, Bandar Tun Razak, 56000 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur.
Tel : +60128388054;
Email : email@example.com
Brunei Int Med J.2022;18:84-88